Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Ixazomib, Thalidomide and Dexamethasone Is an Effective and Well Tolerated Re-Induction Regimen Leading to Salvage Autologous Stem Cell Transplantation (sASCT): Results from the Re-Induction Interim Analysis of UK-MRA Myeloma XII (ACCoRD) Trial

Gordon Cook, Christopher Parrish, MBBChir, MRCP, FRCPath, MA, PhD, Kwee Yong, PhD, Jamie Cavenagh, MD PhD, John A Snowden, MD, Mark T Drayson, Mamta Garg, David Cairns, John Ashcroft, Alina Striha, Anna Hockaday, Ruth M De Tute, BSc,MSc, Roger G. Owen, Cathy Williams, Mark Cook, MBChB,PhD

Blood (2018) 132 (Supplement 1): 255.

https://doi.org/10.1182/blood-2018-99-112116

Published: 2018

Journal Articles

Elective Vs Non-Elective Hospital Admissions By Patients with Multiple Myeloma in England 2014 - 2018

Karthik Ramasamy, MD PhD, Spyros Kolovos, PhD, Guido Nador, MD, Rosemarie Finley, Matthew Streetly, MD, Bhuvan Kishore, Neil K Rabin, MD, Andrew D Chantry, PhD MD, Kwee Yong, MD PhD, John Ashcroft, Stella Bowcock, MD BA, FRCP, FRCPath, MA, Mark T Drayson, Daniel Prieto-Alhambra, PhD MD, Cyrus Cooper, OBE, DL, FMedSci, Muhammad Kassim Javaid, MD PhD, Rafael Pinedo-Villanueva, PhD

Blood (2018) 132 (Supplement 1): 4743.

https://doi.org/10.1182/blood-2018-99-114736

Published: 2018

Journal Articles

Cost-Effectiveness of Newly Emerging Regimens for Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Autologous Stem Cell Transplantation (ASCT) Compared with the Current Standards of Care in EU5

John Ashcroft, Callum Shephard, Ashlie Elnoursi, Christopher Pelligra, Sujith Dhanasiri

Blood (2018) 132 (Supplement 1): 4792.

https://doi.org/10.1182/blood-2018-99-118349

Published: 2018

Journal Articles

Assessing Outcomes, Healthcare Resource Utilisation and Costs across Europe in Newly Diagnosed Multiple Myeloma (NDMM) Patients Post Autologous Stem Cell Transplant (ASCT)

John Ashcroft, Davneet Judge, Sujith Dhanasiri, MSc, Gavin Taylor-Stokes

Blood (2017) 130 (Supplement 1): 4709.

https://doi.org/10.1182/blood.V130.Suppl_1.4709.4709

Published: 2017

Journal Articles

A Systematic Review and Network Meta-Analysis of Maintenance Treatment for Patients with Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplant

Susanne Schmitz, Vanessa Buchanan, Joy Leahy, Sujith Dhanasiri, MSc, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, John Ashcroft

Blood (2017) 130 (Supplement 1): 1832.

https://doi.org/10.1182/blood.V130.Suppl_1.1832.1832

Published: 2017

Journal Articles

Novel Targeted Therapies and Their Impact on Survival from Multiple Myeloma (MM) and Chronic Lymphocytic Leukaemia (CLL) in the Real World

Alexandra G Smith, PhD, Timothy Bagguley, MSc, Eve Roman, PhD, Andy C Rawstron, James R Bailey, MA MBBS MRCP, Debra Howell, PhD, John Ashcroft, MD MBBChir, PhD MRCP, MA, FRCPath, Burton Cathy, Gordon Cook, MD PhD, Russell Patmore, MRCP FRCPath

Blood (2016) 128 (22): 3546.

https://doi.org/10.1182/blood.V128.22.3546.3546

Published: 2016

Journal Articles

Outcomes Following Salvage Autologous Stem Cell Transplant (ASCT2) Vs Low Dose Alkylating Consolidation Therapy Following Bortezomib-Containing Re-Induction for Relapsed Multiple Myeloma (MM) May be Dependent on Age and Symptomatic Status Initiation of Re-Induction: Results from the Myeloma X (Intensive) Trial

John Ashcroft, MD MBBChir, PhD MRCP, MA, FRCPath, David A Cairns, Cathy Williams, A Hockaday, J. D. Cavenagh, MD MRCP, John A Snowden, MD FRCP, FRCPath, Christopher Parrish, MD, Kwee L Yong, MBChB, PhD, Jim Cavet, FRCPath, Hannah Hunter, Jennifer Bird, Guy Pratt, MD, Sally Chown, Earnest Heartin, Sheila J.M. O'Connor, Julia Brown, PhD, Curly Morris, MD, Gordon Cook, MD PhD

Blood (2015) 126 (23): 1981.

https://doi.org/10.1182/blood.V126.23.1981.1981

Published: 2015

Journal Articles

A Salvage Autologous Stem Cell Transplant (ASCT2) Induces Superior Overall Survival Following Bortezomib-Containing Re-Induction Therapy for Relapsed Multiple Myeloma (MM): Results from the Myeloma X (Intensive) Trial

Gordon Cook, MD PhD, Cathy Williams, David A Cairns, Anna Hockaday, Jamie Cavenagh, John A Snowden, MD FRCP, FRCPath, Christopher Parrish, MD, Kwee L Yong, MBChB, PhD, Jim Cavet, FRCPath, Hannah Hunter, Jennifer Bird, Guy Pratt, MD, Sally Chown, Earnest Heartin, Sheila J.M. O'Connor, John Ashcroft, MD MBBChir, PhD MRCP, MA, FRCPath, Julia Brown, PhD, Curly Morris, MD

Blood (2015) 126 (23): 394.

https://doi.org/10.1182/blood.V126.23.394.394

Published: 2015

Journal Articles

Patient-Reported Outcomes (PRO) in the Setting of Relapsed Myeloma: The Influence of Treatment Strategies and Genetic Variants Predict Quality of Life and Pain Experience

Sam H Ahmedzai, MBChB BSc FRCP, John A Snowden, MD FRCP, FRCPath, Angela Cox, BA MA PhD, David A Cairns, Cathy D Williams, Anna Hockaday, Jamie Cavenagh, Christopher Parrish, MD, Kwee L Yong, MBChB, PhD, Jim Cavet, FRCPath, Hannah Hunter, Jennifer Bird, John Ashcroft, MD MBBChir, PhD MRCP, MA, FRCPath, Julia Brown, PhD, Curly Morris, MD, Gordon Cook, MD PhD

Blood (2015) 126 (23): 3180.

https://doi.org/10.1182/blood.V126.23.3180.3180

Published: 2015

Journal Articles

Skeletal-Related Events In Myeloma: A Population-Based Study

John Ashcroft, MD, MBBChir, PhD, MRCP, MA, FRCPath, Bagguley Timothy, MSc, Alexandra Smith, PhD, Han-I Wang, PhD, Debra Howell, PhD, Hazem A Sayala, MBChB, MRCP, Gordon Cook, MD, PhD, Andrew Jack, PhD, Russell Patmore, MD, Eve Roman, PhD

Blood (2013) 122 (21): 3158.

https://doi.org/10.1182/blood.V122.21.3158.3158

Published: 2013

Journal Articles

The Utility Of Minimal Residual Disease (MRD) Assessment At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

John Ashcroft, MD, MBBChir, PhD, MRCP, MA, FRCPath, Ruth M de Tute, MSc, David A Cairns, PhD, Marie Fletcher, Roger G Owen, MD, Andy Rawstron, PhD, Sheila J.M. O'Connor, PhD, Cathy D. Williams, MBBS, MCRP, FRCPath, John A Snowden, MD, FRCP, FRCPath, J. D. Cavenagh, MD, MRCP, Christopher Parrish, MA, MB, BChir, MRCP, Treen Morris, Julia MB Brown, Gordon Cook, MD, PhD

Blood (2013) 122 (21): 3378.

https://doi.org/10.1182/blood.V122.21.3378.3378

Published: 2013

Journal Articles

Interphase FISH Analysis Of Multiple Myeloma Molecular Risk At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

Gordon Cook, MD, PhD, John Ashcroft, MD, MBBChir, PhD, MRCP, MA, FRCPath, Cathy D. Williams, MBBS, MCRP, FRCPath, David A Cairns, PhD, Marie Fletcher, Christopher Parrish, MD, James D. Cavenagh, MD, John A Snowden, MD, FRCP, FRCPath, Sheila J O'Connor, Roger G Owen, MD, Julia Brown, MB, Treen Morris

Blood (2013) 122 (21): 1884.

https://doi.org/10.1182/blood.V122.21.1884.1884

Published: 2013

Journal Articles

Treatment Patterns & Survival In Multiple Myeloma Patients Sequentially Exposed To Thalidomide, Bortezomib & Lenalidomide In a UK Single Centre

Julie L Tarant, MBChB MRCP(UK), John Ashcroft, MD, MBBChir, PhD, MRCP, MA, FRCPath, Sylvia Feyler, MD PhD, Roger G Owen, MD, Christopher Parrish, MA, MB, BChir, MRCP, Gordon Cook, MD, PhD

Blood (2013) 122 (21): 5380.

https://doi.org/10.1182/blood.V122.21.5380.5380

Published: 2013

Journal Articles

A Second Autologous Stem Cell Transplant (ASCT2) Induces Superior Durability Of Response (DuR) Following Bortezomib-Containing Re-Induction Therapy For Relapsed Multiple Myeloma (MM): Final Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

Gordon Cook, MD, PhD, Cathy D. Williams, MBBS, MCRP, FRCPath, David A Cairns, PhD, Marie Fletcher, J. D. Cavenagh, MD, MRCP, John A Snowden, MD, FRCP, FRCPath, Christopher Parrish, MD, John Ashcroft, Kwee L Yong, PhD, Jim Cavet, FRCPath, Hannah Hunter, MB, FRCPath, MRCP, Jennifer Bird, Sheila J O'Connor, Julia MB Brown, Treen Morris

Blood (2013) 122 (21): 765.

https://doi.org/10.1182/blood.V122.21.765.765

Published: 2013

Journal Articles

Overall Safety and Treatment Duration in Lenalidomide (LEN)-, Thalidomide (THAL)-, and Bortezomib (BORT)-Treated Patients (Pts) within the European Post-Approval Safety Study (EU PASS) of Relapsed/Refractory Multiple Myeloma (RRMM)

Barbara Gamberi, Charalampia Kyriakou, John Ashcroft, Miguel T. Hernandez, Jo Caers, Gerard Bos, Maria Asunción Echeveste, Christian Berthou, Renato Zambello, Elisabeth Küenburg, Barbara Rosettani, Brooke Ryder-Smith, Igor W. Blau

Blood (2012) 120 (21): 4068.

https://doi.org/10.1182/blood.V120.21.4068.4068

Published: 2012

Journal Articles

Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial

Gareth J. Morgan, Faith E. Davies, Walter M. Gregory, Alex J. Szubert, Sue E. Bell, Mark T. Drayson, Roger G. Owen, A. John Ashcroft, Graham H. Jackson, J. Anthony Child

Blood (2012) 119 (23): 5374–5383.

https://doi.org/10.1182/blood-2011-11-392522

Published: 2012

Includes: Supplemental data

Journal Articles

Optimising Bone Disease In Myeloma; Zoledronic Acid Plus Thalidomide Combinations Improves Survival and Bone Endpoints: Results of the MRC Myeloma IX Trial

Gareth J Morgan, MD, PhD, Faith E. Davies, MD, Walter M Gregory, Sue E. Bell, DPhil, Alexander J Szubert, MSc, Mark T. Drayson, MD, John Ashcroft, MD, MBBChir, PhD, MRCP, MA, FRCPath, Roger G. Owen, MD, Gordon Cook, MD, Fiona M. Ross, Dr, Graham H. Jackson, MD, Nigel H. Russell, MD, J. Anthony Child, MD

Blood (2010) 116 (21): 311.

https://doi.org/10.1182/blood.V116.21.311.311

Published: 2010

Journal Articles

Feasibility and Efficacy of Administration of Bortezomib-Containing Regimens to Patients Over the Age of 70 Years

Christopher Parrish, MA, MB, BChir, MRCP, Julian Cromack, Sylvia Feyler, MD, MRCP, FRCPath, John Ashcroft, MD, MBBChir, PhD, MRCP, MA, FRCPath, Roger G. Owen, MD, Gordon Cook, MD

Blood (2010) 116 (21): 5035.

https://doi.org/10.1182/blood.V116.21.5035.5035

Published: 2010

Journal Articles

A High Purity Factor VIII/vWF Complex Concentrate Is Effective in the Management of Mild Hemophillia A with Inhibitors: A Case Report.

Srivasavi Dukka, MBBS, MD, MRCP, Susan Kaye, RGN,CNS, John Ashcroft, PhD, Anita Hill, MD, Liakat A. Parapia, FRCP,FRCPE,FRC Path

Blood (2007) 110 (11): 3959.

https://doi.org/10.1182/blood.V110.11.3959.3959

Published: 2007

Journal Articles

Reguatory T-Cell Subsets Demonstrate Quantitative Differences but Not Functional Abnormalities in Patients with Multiple Myeloma (MM) Compared with Healthy Controls.

Sylvia Feyler, MD, Marie von Lilienfeld-Toal, MD, Lee Marles, PhD, Andy Rawstron, PhD, Roger G. Owen, MD, John Ashcroft, PhD, Gordon Cook, PhD

Blood (2007) 110 (11): 3511.

https://doi.org/10.1182/blood.V110.11.3511.3511

Published: 2007

NARROW

Ixazomib, Thalidomide and Dexamethasone Is an Effective and Well Tolerated Re-Induction Regimen Leading to Salvage Autologous Stem Cell Transplantation (sASCT): Results from the Re-Induction Interim Analysis of UK-MRA Myeloma XII (ACCoRD) Trial

Elective Vs Non-Elective Hospital Admissions By Patients with Multiple Myeloma in England 2014 - 2018

Cost-Effectiveness of Newly Emerging Regimens for Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Autologous Stem Cell Transplantation (ASCT) Compared with the Current Standards of Care in EU5

Assessing Outcomes, Healthcare Resource Utilisation and Costs across Europe in Newly Diagnosed Multiple Myeloma (NDMM) Patients Post Autologous Stem Cell Transplant (ASCT)

A Systematic Review and Network Meta-Analysis of Maintenance Treatment for Patients with Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplant

Novel Targeted Therapies and Their Impact on Survival from Multiple Myeloma (MM) and Chronic Lymphocytic Leukaemia (CLL) in the Real World

A Salvage Autologous Stem Cell Transplant (ASCT2) Induces Superior Overall Survival Following Bortezomib-Containing Re-Induction Therapy for Relapsed Multiple Myeloma (MM): Results from the Myeloma X (Intensive) Trial

Patient-Reported Outcomes (PRO) in the Setting of Relapsed Myeloma: The Influence of Treatment Strategies and Genetic Variants Predict Quality of Life and Pain Experience

Skeletal-Related Events In Myeloma: A Population-Based Study

The Utility Of Minimal Residual Disease (MRD) Assessment At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

Interphase FISH Analysis Of Multiple Myeloma Molecular Risk At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

Treatment Patterns & Survival In Multiple Myeloma Patients Sequentially Exposed To Thalidomide, Bortezomib & Lenalidomide In a UK Single Centre

A Second Autologous Stem Cell Transplant (ASCT2) Induces Superior Durability Of Response (DuR) Following Bortezomib-Containing Re-Induction Therapy For Relapsed Multiple Myeloma (MM): Final Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

Overall Safety and Treatment Duration in Lenalidomide (LEN)-, Thalidomide (THAL)-, and Bortezomib (BORT)-Treated Patients (Pts) within the European Post-Approval Safety Study (EU PASS) of Relapsed/Refractory Multiple Myeloma (RRMM)

Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial

Optimising Bone Disease In Myeloma; Zoledronic Acid Plus Thalidomide Combinations Improves Survival and Bone Endpoints: Results of the MRC Myeloma IX Trial

Feasibility and Efficacy of Administration of Bortezomib-Containing Regimens to Patients Over the Age of 70 Years

A High Purity Factor VIII/vWF Complex Concentrate Is Effective in the Management of Mild Hemophillia A with Inhibitors: A Case Report.

Reguatory T-Cell Subsets Demonstrate Quantitative Differences but Not Functional Abnormalities in Patients with Multiple Myeloma (MM) Compared with Healthy Controls.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only